| Literature DB >> 29457026 |
In Young Jung1,2, Jung Ju Kim1,2, Se Ju Lee1,2, Jinnam Kim1,2, Hye Seong1,2, Wooyong Jeong1,2, Heun Choi1,2, Su Jin Jeong1,2, Nam Su Ku1,2, Sang Hoon Han1,2, Jun Yong Choi1,2, Young Goo Song1,2, Jung Won Park1,3, June Myung Kim1,2.
Abstract
BACKGROUND: Adverse drug reactions (ADRs) are any unwanted/uncomfortable effects from medication resulting in physical, mental, and functional injuries. Antibiotics account for up to 40.9% of ADRs and are associated with several serious outcomes. However, few reports on ADRs have evaluated only antimicrobial agents. In this study, we investigated antibiotic-related ADRs at a tertiary care hospital in South Korea.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29457026 PMCID: PMC5804292 DOI: 10.1155/2017/4304973
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Frequency (%) of adverse drug reaction types and serious adverse drug reactions.
Antibiotics related ADR frequency and most common symptoms according to organ class (according to the preferred terms of MedDRA coding system).
| Antibiotic | Patients, | Symptom organ class | Frequency of |
|---|---|---|---|
| Penicillin | 204 (16) | Skin and subcutaneous tissue | 88 (43.1) |
|
| |||
| Quinolone | 204 (16) | Skin and subcutaneous tissue | 98 (48.0) |
|
| |||
| 3rd cephalosporin | 190 (14.9) | Skin and subcutaneous tissue | 86 (45.3) |
|
| |||
| 2nd cephalosporin | 144 (11.3) | Skin and subcutaneous tissue | 68 (47.2) |
|
| |||
| Glycopeptide | 134 (10.5) | Skin and subcutaneous tissue | 83 (61.9) |
|
| |||
| Metronidazole | 61 (4.8) | Gastrointestinal | 46 (75.4) |
|
| |||
| Antituberculosis medication | 61 (4.8) | Skin and subcutaneous tissue | 33 (54.1) |
|
| |||
| 1st cephalosporin | 53 (4.2) | Skin and subcutaneous tissue | 32 (60.4) |
|
| |||
| Carbapenem | 43 (3.4) | Skin and subcutaneous tissue | 19 (44.2) |
|
| |||
| Antifungal | 33 (2.6) | Allergic | 12 (36.4) |
|
| |||
| Antiviral | 21 (1.6) | Skin and subcutaneous tissue | 8 (38.1) |
|
| |||
| Aminoglycoside | 20 (1.6) | Skin and subcutaneous tissue | 12 (60.0) |
|
| |||
| Macrolide | 17 (1.3) | Gastrointestinal | 7 (41.2) |
|
| |||
| Sulfonamide | 16 (1.3) | Gastrointestinal | 9 (56.2) |
|
| |||
| 4th cephalosporin | 16 (1.3) | Skin and subcutaneous tissue | 9 (56.2) |
|
| |||
| Tetracycline | 13 (1) | Gastrointestinal | 8 (61.5) |
|
| |||
| Antimalarial | 12 (0.9) | Skin and subcutaneous tissue | 5 (41.7) |
|
| |||
| Lincosamide | 9 (0.7) | Skin and subcutaneous tissue | 7 (77.8) |
|
| |||
| Polymyxin | 3 (0.2) | Renal and urinary | 2 (66.7) |
|
| |||
| Monobactam | 1 (0.1) | Allergic | 1 (100) |
|
| |||
| Linezolid | 1 (0.1) | Blood and lymphatic system | 1 (100) |
ADRs: adverse drug reactions.
Figure 2Frequency (%) of adverse drug reaction in symptom organ class.
Frequency of ADRs in symptom organ class and most common causative antibiotics (according to the preferred terms of MedDRA coding system).
| Symptom organ class | Patients, | Antibiotics | Frequency of ADRs, |
|---|---|---|---|
| Skin and subcutaneous tissue disorders | 576 (45.1) | Quinolone | 98 (17.0) |
|
| |||
| Gastrointestinal disorders | 416 (32.6) | 3rd cephalosporin | 79 (19.0) |
|
| |||
| Allergic disorders | 125 (9.8) | Glycopeptide | 24 (19.2) |
|
| |||
| Nervous system disorders | 91 (7.1) | Quinolone | 16 (17.6) |
|
| |||
| Blood and lymphatic system disorders | 68 (5.3) | Penicillin | 20 (29.4) |
|
| |||
| Cardiac disorders | 43 (3.4) | Quinolone | 8 (18.6) |
|
| |||
| General disorders and administration site conditions | 31 (2.4) | Quinolone | 11 (61.1) |
|
| |||
| Renal and urinary disorders | 24 (1.9) | Glycopeptide | 5 (20.8) |
|
| |||
| Respiratory, thoracic, and mediastinal disorders | 23 (1.8) | 3rd cephalosporin | 6 (26.1) |
|
| |||
| Hepatobiliary disorders | 23 (1.8) | Anti-TB medication | 6 (26.1) |
|
| |||
| Eye disorder | 5 (0.4) | Anti-TB medication | 4 (80.0) |
|
| |||
| Psychiatric disorders | 4 (0.3) | 2nd cephalosporin | 2 (50.0) |
|
| |||
| Musculoskeletal and connective tissue disorders | 2 (0.2) | Penicillin | 1 (50.0) |
ADRs: adverse drug reactions; TB: tuberculosis.